Question

求翻译这段话！

Imeglimin is a novel agent currently in development to treat type 2 diabetes. Laboratory studies have demonstrated that it has the potential to impact the three
main pathophysiologic components of type 2 diabetes:impaired glucose uptake by muscle tissue, excess hepatic gluconeogenesis, and increased beta-cell apoptosis. Preliminary human studies that have been published within the last 2 years demonstrate that imeglimin improves hemoglobin A1c and fasting plasma glucose similarly when compared with metformin and with sitagliptin. There has also been a low incidence of adverse effects, especially hypoglycemia, reported in these early human studies.Currently, imeglimin is lacking long-term evidence to demonstrate any effects on its cardiovascular safety, and data on morbidity and mortality, though some studies are currently in progress. There is great potential for imeglimin, if FDA approved, to play a significant role in the type 2 diabetes management algorithm.

Answer 1

Imeglimin是一种新型药物目前正在开发用于治疗2型糖尿病。实验室研究表明，它具有三个主要的病理生理成分的影响2型糖尿病的潜力：葡萄糖的摄取受损的肌肉组织，多余的肝糖异生，与β细胞凋亡增加。已经公布在过去的2年里，人类的研究表明，临床初步改善糖化血红蛋白和空腹血糖与二甲双胍和西他列汀相比。也有一个低的不良影响，特别是低血糖的发生率，在这些早期的人类研究的报告。目前，Imeglimin是缺乏长期的证据表明其心血管安全性的任何影响，并对死亡率和发病率的数据，虽然有些是目前的研究进展。还有很大潜力Imeglimin，如果FDA批准，在2型糖尿病管理算法中发挥重要作用